A discussion unfolds around the missteps in drug development, particularly with a CETP inhibitor that initially showed promise. Despite a significant increase in HDL cholesterol, unforeseen side effects, including elevated blood pressure, led to disastrous outcomes. The conversation highlights the critical importance of understanding drug effects before advancing to larger trials, emphasizing the lessons learned from this failure in cardiovascular drug research.
